grant

Immunologic and Predictive Features of MIS-C

Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 18 Jul 2022Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY20250-11 years old2019 novel corona virus2019 novel coronavirus2019-nCoV21+ years oldActive Follow-upAcuteAdultAdult HumanAgeAlgorithmsAntibody RepertoireAreaAssayAutoantibodiesBioassayBiologicalBiological AssayBiological MarkersBloodBlood Reticuloendothelial SystemCITE sequencingCITE-seqCITEseqCOVID crisisCOVID epidemicCOVID pandemicCOVID-19COVID-19 antibodyCOVID-19 associated deathCOVID-19 associated fatalityCOVID-19 associated mortalityCOVID-19 crisisCOVID-19 deathCOVID-19 epidemicCOVID-19 eraCOVID-19 fatalityCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 induced deathCOVID-19 induced fatalityCOVID-19 induced mortalityCOVID-19 infectionCOVID-19 mortalityCOVID-19 pandemicCOVID-19 periodCOVID-19 positiveCOVID-19 positivityCOVID-19 public health crisisCOVID-19 related deathCOVID-19 related fatalityCOVID-19 related mortalityCOVID-19 virusCOVID-19 virus infectionCOVID-19 yearsCOVID19 associated deathCOVID19 associated fatalityCOVID19 associated mortalityCOVID19 deathCOVID19 fatalityCOVID19 induced deathCOVID19 induced fatalityCOVID19 induced mortalityCOVID19 infectionCOVID19 mortalityCOVID19 related deathCOVID19 related fatalityCOVID19 related mortalityCOVID19 virusCV-19Cell BodyCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCharacteristicsChildChild DevelopmentChild YouthChildhoodChildren (0-21)Circulatory CollapseClinicalCoV diseaseCoV-2CoV2Computer ModelsComputerized ModelsCoronavirus Infectious Disease 2019Critical CareDataData CollectionData SetDevelopmentDiagnosisDiseaseDisease OutbreaksDisorderDysfunctionFunctional disorderGeneticGenomicsIRBIRBsImmuneImmunesImmunochemical ImmunologicImmunologicImmunologic SubtypingImmunologicalImmunologicallyImmunologicsImmunophenotypingIndividualInfant and Child DevelopmentInfectionInflammationInflammatoryInfluenza AInfluenza A virusInfluenza BInfluenza B VirusInfluenza Viruses Type AInfluenza Viruses Type BInfluenzavirus AInstitutional Review BoardsKawasaki DiseaseLifeLondonMIS-CMachine LearningMapsMeasurementModelingMononuclearMorbidityMorbidity - disease rateMucocutaneous Lymph Node SyndromeMultiorgan Inflammatory Syndrome in ChildrenMultisystem Inflammatory Syndrome in ChildrenNew York CityOrthomyxovirus Type AOrthomyxoviruses Type BOutbreaksOutcomePathogenesisPatientsPhasePhysiopathologyPneumoniaPredicting RiskPrognosisPublishingRelative RisksReportingRespiratory DiseaseRespiratory System DiseaseRespiratory System DisorderRiskRisk AssessmentRisk-associated variantSARS VirusSARS corona virusSARS corona virus 2SARS coronavirusSARS-Associated CoronavirusSARS-CO-V2SARS-COVID-2SARS-CoVSARS-CoV-1SARS-CoV-2SARS-CoV-2 antibodySARS-CoV-2 associated deathSARS-CoV-2 associated fatalitySARS-CoV-2 associated mortalitySARS-CoV-2 deathSARS-CoV-2 epidemicSARS-CoV-2 fatalitySARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 induced deathSARS-CoV-2 induced fatalitySARS-CoV-2 induced mortalitySARS-CoV-2 infectionSARS-CoV-2 mortalitySARS-CoV-2 pandemicSARS-CoV-2 positiveSARS-CoV-2 positivitySARS-CoV-2 related deathSARS-CoV-2 related fatalitySARS-CoV-2 related mortalitySARS-CoV2SARS-CoV2 infectionSARS-Related CoronavirusSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SamplingSerologySevere Acute Respiratory CoronavirusSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere Acute Respiratory Syndrome VirusSevere Acute Respiratory Syndrome corona virusSevere Acute Respiratory Syndrome coronavirusSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 positiveSevere acute respiratory syndrome coronavirus 2 positivitySevere acute respiratory syndrome related corona virus 2ShockSiteSpainSurfaceSymptomsSyndromeTechnologyTimeType A InfluenzaVirusWorld Health OrganizationWuhan coronavirusactive followupadulthoodafter COVID-19 infectionafter SARS-CoV-2 infectionafter SARS-CoV2 infectionafter infection by SARS-CoV-2after severe acute respiratory distress syndrome CoV-2 infectionagesantibody against COVID-19antibody against SARS-CoV-2antibody against coronavirus disease 2019antibody against severe acute respiratory syndrome coronavirus 2antibody to COVID-19antibody to SARS-CoV-2antibody to coronavirus disease 2019antibody to severe acute respiratory syndrome coronavirus 2autoimmune antibodyautoreactive antibodybio-markersbiologicbiologic markerbiomarkerbiomarker identificationcellular indexing of transcriptomes and epitopes by single cell sequencingchild patientscirculatory shockclinical centercohortcompare to controlcomparison controlcomputational modelingcomputational modelscomputer based modelscomputerized modelingcorona virus diseasecoronavirus diseasecoronavirus disease 2019coronavirus disease 2019 antibodycoronavirus disease 2019 associated deathcoronavirus disease 2019 associated fatalitycoronavirus disease 2019 associated mortalitycoronavirus disease 2019 crisiscoronavirus disease 2019 deathcoronavirus disease 2019 epidemiccoronavirus disease 2019 fatalitycoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 induced deathcoronavirus disease 2019 induced fatalitycoronavirus disease 2019 induced mortalitycoronavirus disease 2019 infectioncoronavirus disease 2019 mortalitycoronavirus disease 2019 pandemiccoronavirus disease 2019 positivecoronavirus disease 2019 positivitycoronavirus disease 2019 public health crisiscoronavirus disease 2019 related deathcoronavirus disease 2019 related fatalitycoronavirus disease 2019 related mortalitycoronavirus disease 2019 viruscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19coronavirus disease-19 global pandemiccoronavirus disease-19 mortalitycoronavirus disease-19 pandemiccoronavirus disease-19 viruscoronavirus infectious disease-19death due to COVID-19death due to COVID19death due to SARS-CoV-2death due to coronavirus disease 2019death due to severe acute respiratory syndrome coronavirus 2death in COVIDdeath in COVID-19death in SARS-CoV-2death in coronavirus diseasedeath in coronavirus disease 2019death in severe acute respiratory syndrome coronavirus 2developmentaldisease diagnosisdisease prognosisdisease prognosticationdisease riskdisorder riskearly childhoodexome sequencingexome-seqfatality due to COVID-19fatality due to COVID19fatality due to SARS-CoV-2fatality due to coronavirus disease 2019fatality due to severe acute respiratory syndrome coronavirus 2follow upfollow-upfollowed upfollowing COVID-19 infectionfollowing SARS-CoV-2 infectionfollowing SARS-CoV2 infectionfollowing infection by SARS-CoV-2following severe acute respiratory distress syndrome CoV-2 infectionfollowupforecasting riskhCoV19identification of biomarkersidentification of new biomarkersimprovedinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2infection ratekidslong-term sequelaemachine based learningmachine learned algorithmmachine learning algorithmmachine learning based algorithmmachine learning based methodmachine learning methodmachine learning methodologiesmarker identificationmortality due to COVID-19mortality due to COVID19mortality due to SARS-CoV-2mortality due to coronavirus disease 2019mortality due to severe acute respiratory syndrome coronavirus 2multisystem inflammatory syndrome of childrennCoV2novelpathogenpathophysiologypediatricpediatric inflammatory multisystem syndromepediatric patientspost SARS-CoV-2 infectionpredict riskpredict riskspredicted riskpredicted riskspredicting riskspredictive riskpredicts riskprevious COVID-19 infectionprevious SARS-CoV-2 infectionprevious SARS-CoV2 infectionprevious severe acute respiratory distress syndrome CoV-2 infectionprior COVID-19 infectionprior SARS-CoV-2 infectionprior SARS-CoV2 infectionprior severe acute respiratory distress syndrome CoV-2 infectionrate of infectionrecruitrisk allelerisk generisk genotyperisk locirisk locusrisk predictionrisk predictionsrisk stratificationrisk variantscRNA sequencingscRNA-seqself reactive antibodysevere acute respiratory syndrome coronavirus 2 antibodysevere acute respiratory syndrome coronavirus 2 associated deathsevere acute respiratory syndrome coronavirus 2 associated fatalitysevere acute respiratory syndrome coronavirus 2 associated mortalitysevere acute respiratory syndrome coronavirus 2 deathsevere acute respiratory syndrome coronavirus 2 fatalitysevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsevere acute respiratory syndrome coronavirus 2 induced deathsevere acute respiratory syndrome coronavirus 2 induced fatalitysevere acute respiratory syndrome coronavirus 2 induced mortalitysevere acute respiratory syndrome coronavirus 2 mortalitysevere acute respiratory syndrome coronavirus 2 related deathsevere acute respiratory syndrome coronavirus 2 related fatalitysevere acute respiratory syndrome coronavirus 2 related mortalitysevere acute respiratory syndrome-CoVshockssingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingstratify riskyoungster
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

The novel SARS coronavirus (SARS-CoV-2) causes the severe pneumonia-like coronavirus
disease (COVID-19). SARS-CoV-2 infected over 170 million individuals and has claimed over

3.5 million lives worldwide to date. If otherwise healthy, children were thought to be largely

spared from SARS-CoV-2 disease. However, in areas of high SARS-CoV-2 infection rates,

some children started presenting to pediatric critical care units 4-6 weeks following SARS-CoV-

2 infection with Kawasaki-like disease. Clinically, we now know that this is a distinct disease,

which was recently termed - multisystem inflammatory syndrome in children (MIS-C). While the

characteristic clinical features of MIS-C are becoming clear, the pathophysiology remains

unknown. Here we propose to evaluate three independent cohorts of MIS-C during acute and

convalescent phases of disease at clinical, genetic and immunologic levels using the latest

technology. We will not only perform systemic immunological mapping of MIS-C as compared to

controls, but also utilize machine learning algorithms to delineate how best to predict, diagnose

and outcome stratify MIS-C. We anticipate discovering immunologic and genetic features which

can aid us in assessing risks of MIS-C development, diagnosis and prognosis. In summary, our

systematic analysis and computational modeling of the clinical and immune features of MIS-C

will not only help illuminate the pathogenesis of this syndrome, but will also provide us with

actionable biomarkers for disease risk, diagnosis and progression.

Grant Number: 5R01HD108467-05
NIH Institute/Center: NIH

Principal Investigator: Dusan Bogunovic

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →